TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 2255839
Drug: Ivermectin 150
Normalized name: Ivermectin
DrugBank: Ivermectin (DB00602)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Ivermectin 150 mcg/kg
Study: 20695208
Drug: Cycloferon (injections
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cycloferon (injections and tablets)
Study: 20695208
Drug: Triple therapy
Normalized name: MigreLief Triple Therapy with Puracol Caplet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Triple therapy with immunomodulators (including cycloferon, galavit, and derinat)
Study: 18156372
Drug: Prescription only
Approvals — FDA: no, EMA: no, PMDA: no
Description: Prescription only (arm B)
Study: 16785215
Drug: Symptom-triggered (ST)
Normalized name: Pamprin Multi-Symptom
Approvals — FDA: no, EMA: no, PMDA: no
Description: Symptom-triggered (ST) dosing of lorazepam based on CIWA-Ar score
Study: 16785215
Drug: Fixed-schedule (FS)
Normalized name: Humalog Mix
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fixed-schedule (FS) dosing of lorazepam with tapering over 4 days
Study: 14605453
Drug: Unconventional anti-cancer
Normalized name: Anti Bac
Approvals — FDA: no, EMA: no, PMDA: no
Description: Unconventional anti-cancer drugs
Study: 10830255
Drug: Systemic corticosteroids
Normalized name: CORTICOSTEROIDS FOR SYSTEMIC USE
Approvals — FDA: no, EMA: no, PMDA: no
Description: Systemic corticosteroids administered within the first 2 weeks of life
Study: 10830255
Drug: Diuretics and
Normalized name: Low-ceiling diuretics and potassium-sparing agents
Approvals — FDA: no, EMA: no, PMDA: no
Description: Diuretics and inhaled bronchodilators
Study: 10830255
Drug: Alpha-1 proteinase
Normalized name: alpha-1 proteinase inhibitor
DrugBank: Alpha-1-proteinase inhibitor (DB00058)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Alpha-1 proteinase inhibitor
Study: 1727807
Drug: 300 mg
Normalized name: rutin 300 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 300 mg MEL administered daily (days 1-30) for 4 months
Study: 1727807
Drug: 300 mg
Normalized name: rutin 300 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 300 mg MEL (days 5-17) and 75 mg MEL combined with 0.3 mg NET
Study: 6371876
Drug: Trazodone 50-200
Approvals — FDA: no, EMA: no, PMDA: no
Description: Trazodone 50-200 mg once daily for 5 weeks
Study: 6371876
Drug: Doxepin 25-100
Normalized name: doxepin 25 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Doxepin 25-100 mg once daily for 5 weeks
Study: 24676877
Drug: Tasisulam sodium
Normalized name: Tasisulam
DrugBank: Tasisulam (DB11941)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tasisulam sodium (targeting an albumin‐corrected exposure of 1200‐6400 h.μg/mL on day 1)
Study: 24676877
Drug: Paclitaxel (80
Approvals — FDA: no, EMA: no, PMDA: no
Description: Paclitaxel (80 mg/m² on days 1, 8, and 15 every 28 days)
Study: 20178538
Drug: HPV-16/18 AS04-adjuvanted
Approvals — FDA: no, EMA: no, PMDA: no
Description: HPV-16/18 AS04-adjuvanted cervical cancer vaccine
Study: 16101180
Drug: Docetaxel 60
Normalized name: Docetaxel
DrugBank: Docetaxel (DB01248)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Docetaxel 60 mg/m2 i.v. followed by irinotecan 200 mg/m2 i.v. on day 1 with rhG-CSF support from days 2 to 6, every 3 weeks
Study: 11834957
Drug: Cidofovir Treatment
Normalized name: Cidofovir
DrugBank: Cidofovir (DB00369)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Cidofovir Treatment (CT)
Study: 11834957
Drug: Surgical-Cidofovir Treatment
Normalized name: Cidofovir
DrugBank: Cidofovir (DB00369)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Surgical-Cidofovir Treatment (SCT)
Study: 7717184
Drug: PETN (150
Approvals — FDA: no, EMA: no, PMDA: no
Description: PETN (150 mg b.i.d.)
Study: 2149509
Drug: Buserelin (nasal
Approvals — FDA: no, EMA: no, PMDA: no
Description: Buserelin (nasal spray, 3 daily doses of 400 micrograms) combined with cyproterone acetate (CPA, 3 daily doses of 50 mg orally for 2 weeks)
Study: 2149509
Drug: Orchidectomy (standard
Approvals — FDA: no, EMA: no, PMDA: no
Description: Orchidectomy (standard androgen-deprivative therapy)
Study: 25479571
Drug: 0.8 g
Normalized name: Alcohol 0.8 g in 1 mL TOPICAL LIQUID
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.8 g protein per kg body weight per day
Study: 25479571
Drug: 1.6 g
Normalized name: GLYCERIN 1241.6 g in 1 L TOPICAL LIQUID
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1.6 g protein per kg body weight per day
Study: 25479571
Drug: 2.4 g
Normalized name: ZINC OXIDE 12.4 g in 100 g TOPICAL CREAM
Approvals — FDA: no, EMA: no, PMDA: no
Description: 2.4 g protein per kg body weight per day
Study: 9555667
Drug: Exogenous norepinephrine
Approvals — FDA: no, EMA: no, PMDA: no
Description: Exogenous norepinephrine (NE) at pressor doses (delta MAP = 20 mmHg)
Study: 7995145
Drug: Preoperative radiotherapy
Normalized name: povidone-iodine
DrugBank: Povidone-iodine (DB06812)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Preoperative radiotherapy (20 Gy total, divided into four daily fractions of 5 Gy each)
Study: 2908216
Drug: Chlordesmethyldiazepam 0.1
Approvals — FDA: no, EMA: no, PMDA: no
Description: Chlordesmethyldiazepam 0.1 mg/kg i.v. (group C)
Study: 2908216
Drug: Sodium thiopental
Normalized name: Thiopental Sodium
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sodium thiopental 5 mg/kg i.v. (group T)
Study: 24646366
Drug: Daily interval
Approvals — FDA: no, EMA: no, PMDA: no
Description: Daily interval training until a 25% decrement in time-to-fatigue performance (Study 1)
Study: 22505376
Drug: Topical isosorbide
Approvals — FDA: no, EMA: no, PMDA: no
Description: Topical isosorbide dinitrate 10%
Study: 22505376
Drug: Topical isosorbide
Approvals — FDA: no, EMA: no, PMDA: no
Description: Topical isosorbide dinitrate 5%
Study: 22505376
Drug: Symptomatic treatments
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Symptomatic treatments (control group)
Study: 17613297
Drug: Intravenous ghrelin
Normalized name: Ghrelin
DrugBank: Lenomorelin (DB11895)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous ghrelin (5 pmol/kg/min) infusion
Study: 8335833
Drug: Captopril (sulfhydryl‐containing
Approvals — FDA: no, EMA: no, PMDA: no
Description: Captopril (sulfhydryl‐containing angiotensin‐converting enzyme inhibitor)
Study: 8335833
Drug: Intracoronary nitroglycerin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intracoronary nitroglycerin (1‐ to 20‐micrograms doses)
Study: 2445091
Drug: YM-12617 (0.2
Approvals — FDA: no, EMA: no, PMDA: no
Description: YM-12617 (0.2 mg)
Study: 2445091
Drug: YM-12617 (0.4
Approvals — FDA: no, EMA: no, PMDA: no
Description: YM-12617 (0.4 mg)
Study: 2967855
Drug: Atrial natriuretic
Normalized name: Atrial natriuretic factor
DrugBank: Atrial natriuretic peptide (DB15591)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Atrial natriuretic peptide infusion (0.3 micrograms/kg per min)
Study: 2967855
Drug: Atrial natriuretic
Normalized name: Atrial natriuretic factor
DrugBank: Atrial natriuretic peptide (DB15591)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Atrial natriuretic peptide infusion (0.1 microgram/kg per min)
Study: 31517396
Drug: Insulin‐like growth
Approvals — FDA: no, EMA: no, PMDA: no
Description: Insulin‐like growth factor binding protein 1
Study: 31517396
Drug: Insulin‐like growth
Approvals — FDA: no, EMA: no, PMDA: no
Description: Insulin‐like growth factor binding protein 5
Study: 26051546
Drug: Conventional method
Approvals — FDA: no, EMA: no, PMDA: no
Description: Conventional method (custom tray with impression compound and silicone)
Study: 11587609
Drug: Mitomycin (0.4
Approvals — FDA: no, EMA: no, PMDA: no
Description: Mitomycin (0.4 mg/mL, 2 mL solution applied for 2 minutes)
Study: 9156373
Drug: sirolimus (0.5‐6.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: sirolimus (0.5‐6.5 mg/m2/12 hr)
Study: 3331375
Drug: Clomiphene citrate
Normalized name: Clomiphene Citrate
DrugBank: Clomifene (DB00882)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Clomiphene citrate (CC) and Tamoxifen (TAM)
Study: 23370582
Drug: Water-based exercise
Normalized name: benzoyl peroxide
DrugBank: Benzoyl peroxide (DB09096)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Water-based exercise (at least twice-weekly for 8 weeks)
Study: 8408733
Drug: Quinidine sulfate
Normalized name: Quinidine Sulfate
DrugBank: Quinidine (DB00908)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Quinidine sulfate (200 mg orally)
Study: 8408733
Drug: Nifedipine-quinidine combination
Normalized name: nifedipine, combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nifedipine-quinidine combination
Study: 3760461
Drug: Bromocriptine (5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Bromocriptine (5 mg/day for 5 days)
Study: 30333336
Drug: Tranexamic acid
Normalized name: Tranexamic Acid
DrugBank: Tranexamic acid (DB00302)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Tranexamic acid (3 g in 100 ml saline solution)
Study: 30333336
Drug: Saline solution
Normalized name: Unisol 4 Saline Solution
DrugBank: Sodium chloride (DB09153)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Saline solution (placebo, 100 ml)
Study: 22349673
Drug: Ketamine-propofol-dexmedetomidine combination
Normalized name: Propofol
DrugBank: Propofol (DB00818)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Ketamine-propofol-dexmedetomidine combination (KPD group, n = 30)
Study: 22349673
Drug: Ketamine-propofol combination
Normalized name: Propofol
DrugBank: Propofol (DB00818)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Ketamine-propofol combination (KP group, n = 30)
Study: 17509069
Drug: Metformin (titrated
Approvals — FDA: no, EMA: no, PMDA: no
Description: Metformin (titrated to 2000 mg daily)
Study: 12424384
Drug: Moderate doses
Approvals — FDA: no, EMA: no, PMDA: no
Description: Moderate doses of alcohol
Study: 9523805
Drug: 2.5 ml
Normalized name: syringe, disposable, 2.5 mL
Approvals — FDA: no, EMA: no, PMDA: no
Description: 2.5 ml 2% lidocaine in 7.5% glucose
Study: 2672786
Drug: Methylphenidate (0.3
Approvals — FDA: no, EMA: no, PMDA: no
Description: Methylphenidate (0.3 mg/kg per dose, administered at 8 AM and 12 PM on school days)
Study: 1103209
Drug: marihuana containing
Normalized name: fish oil (containing omega-3 acids) Injection [Omegaven]
Approvals — FDA: no, EMA: no, PMDA: no
Description: marihuana containing 20 mg Delta‐9‐tetrahydrocannabinol
Study: 28241355
Drug: Testosterone gel
Normalized name: Androgel 1.62% Metered Dose Pump Testosterone Gel
DrugBank: (1,2,6,7-3H)Testosterone (DB14093)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Testosterone gel for 12 months
Study: 28241355
Drug: Placebo gel
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo gel for 12 months
Study: 26897544
Drug: Vocal group
Normalized name: Streptococcus viridans group
Approvals — FDA: no, EMA: no, PMDA: no
Description: Vocal group therapy intervention
Study: 23040521
Drug: High-dose arginine
Normalized name: Arginine
DrugBank: Arginine (DB00125)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: High-dose arginine (500 mg · kg(‐1) · d(‐1))
Study: 23040521
Drug: Low-dose arginine
Normalized name: Arginine
DrugBank: Arginine (DB00125)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Low-dose arginine (100 mg · kg(‐1) · d(‐1)) combined with sodium phenylbutyrate (500 mg · kg(‐1) · d(‐1))
Study: 17426000
Drug: Cephalothin V
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cephalothin V (2.0 g) intravenous 30 min before the operation
Study: 17426000
Drug: Ozone injection
Normalized name: ozone
DrugBank: Ozone (DB12510)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ozone injection (6-10 ml ozone at 40 microg/ml) into the discs and 10 ml ozone into the paravertebral space
Study: 15668261
Drug: No axillary
Approvals — FDA: no, EMA: no, PMDA: no
Description: No axillary treatment
Study: 7879930
Drug: Dexmedetomidine low
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dexmedetomidine low dose (targeting plasma concentration of 0.15 ng/ml)
Study: 7879930
Drug: Dexmedetomidine medium
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dexmedetomidine medium dose (targeting plasma concentration of 0.30 ng/ml)
Study: 7879930
Drug: Dexmedetomidine high
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dexmedetomidine high dose (targeting plasma concentration of 0.45 ng/ml)
Study: 26814038
Drug: Intranasal dexmedetomidine
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intranasal dexmedetomidine 3 mcg · kg(‐1) plus oral placebo (Group IN DEX)
Study: 26814038
Drug: Oral chloral
Normalized name: Chloral Hydrate
DrugBank: Chloral hydrate (DB01563)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral chloral hydrate 50 mg · kg(‐1) plus intranasal saline placebo (Group CH)
Study: 26922170
Drug: Pemetrexed and
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pemetrexed and bevacizumab maintenance therapy
Study: 21289261
Drug: 300 mg
Normalized name: rutin 300 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 300 mg of progesterone
Study: 16707870
Drug: No treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: No treatment (erosion only)
Study: 15013894
Drug: Daily patching
Approvals — FDA: no, EMA: no, PMDA: no
Description: Daily patching (> or =2 hours a day) combined with at least 1 hour of near activities
Study: 11709795
Drug: Oral washes
Normalized name: Zencia Wash
DrugBank: Octasulfur (DB09353)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral washes using a PCR detection system based on Pneumocystis major surface glycoprotein primers
Study: 11709795
Drug: Oral washes
Normalized name: Zencia Wash
DrugBank: Octasulfur (DB09353)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral washes using a PCR detection system based on mitochondrial large subunit rRNA primers
Study: 9041342
Drug: 40‐microg S
Approvals — FDA: no, EMA: no, PMDA: no
Description: 40‐microg S subunit vaccine
Study: 9041342
Drug: 10‐microg S
Approvals — FDA: no, EMA: no, PMDA: no
Description: 10‐microg S subunit vaccine
Study: 9041342
Drug: mixed particle
Normalized name: Humalog Mix
Approvals — FDA: no, EMA: no, PMDA: no
Description: mixed particle vaccine (pre‐S1, pre‐S2, and S subunit particles)
Study: 2152972
Drug: ACTH(4-9) analogue,
Approvals — FDA: no, EMA: no, PMDA: no
Description: ACTH(4-9) analogue, Org 2766 (high dose: 1 mg/m²)
Study: 2152972
Drug: ACTH(4-9) analogue,
Approvals — FDA: no, EMA: no, PMDA: no
Description: ACTH(4-9) analogue, Org 2766 (low dose: 0.25 mg/m²)
Study: 7510078
Drug: FK‐506 intelligent
Approvals — FDA: no, EMA: no, PMDA: no
Description: FK‐506 intelligent dosing system (IDS)
Study: 2133624
Drug: 1.5 g
Normalized name: Vaporizer Vicks 1.5 gal
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1.5 g Mg pidolate (MAG2) three times a day for one month
Study: 30311367
Drug: Dapagliflozin (5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dapagliflozin (5 mg per day)
Study: 28588304
Drug: Energy-restriction treatments
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Energy-restriction treatments (VLCK and LC diets)
Study: 24381190
Drug: 400 μg
Approvals — FDA: no, EMA: no, PMDA: no
Description: 400 μg of salbutamol
Study: 23172751
Drug: Lupuzor (200
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lupuzor (200 μg) subcutaneously every 4 weeks
Study: 23172751
Drug: Lupuzor (200
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lupuzor (200 μg) subcutaneously every 2 weeks
Study: 19309420
Drug: Home-based intervention
Approvals — FDA: no, EMA: no, PMDA: no
Description: Home-based intervention training parents to work with children through modelling and coaching by teachers during weekly home visits
Study: 16397402
Drug: 5‐HT2A -1438
Approvals — FDA: no, EMA: no, PMDA: no
Description: 5‐HT2A -1438 A/G polymorphism
Study: 8237402
Drug: Lomefloxacin tablet
DrugBank: Lomefloxacin (DB00978)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Lomefloxacin tablet (400 mg)
Study: 8237402
Drug: Lomefloxacin capsule
Normalized name: lomefloxacin Oral Capsule
DrugBank: Lomefloxacin (DB00978)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Lomefloxacin capsule (400 mg)
Study: 3524844
Drug: Rociverine 20
Normalized name: rociverine
DrugBank: Rociverine (DB13581)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Rociverine 20 mg
Study: 3524844
Drug: Flavoxate 200
Normalized name: flavoxate 200 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Flavoxate 200 mg
Study: 10227010
Drug: Estrogen-progestin therapy
Normalized name: estrogens
Approvals — FDA: no, EMA: no, PMDA: no
Description: Estrogen-progestin therapy
Study: 23796998
Drug: Zoledronic acid
Normalized name: Zoledronic Acid
DrugBank: Zoledronic acid (DB00399)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Zoledronic acid (4 mg for 19 doses over 5 years)
Study: 23796998
Drug: Control (standard
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control (standard adjuvant systemic therapy alone)
Study: 20842110
Drug: Esomeprazole 20
Normalized name: esomeprazole 20 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Esomeprazole 20 or 40 mg daily for 4 weeks
Study: 20842110
Drug: Control group
Normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control group (continued current therapy)
Study: 18613278
Drug: Control (placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control (placebo or active diabetes medications)
Study: 18613278
Drug: Rosiglitazone monotherapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Rosiglitazone monotherapy versus placebo
Study: 18613278
Drug: Rosiglitazone monotherapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Rosiglitazone monotherapy versus sulfonylurea/metformin monotherapy
Study: 18613278
Drug: Sulfonylurea +
Normalized name: sulfanilylurea
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sulfonylurea + rosiglitazone versus sulfonylurea monotherapy
Study: 18613278
Drug: Metformin +
Approvals — FDA: no, EMA: no, PMDA: no
Description: Metformin + rosiglitazone versus metformin monotherapy
Study: 18613278
Drug: Metformin +
Approvals — FDA: no, EMA: no, PMDA: no
Description: Metformin + rosiglitazone versus metformin + sulfonylurea
Study: 18613278
Drug: Sulfonylurea +
Normalized name: sulfanilylurea
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sulfonylurea + metformin + rosiglitazone versus sulfonylurea + metformin
Study: 18613278
Drug: Insulin +
Normalized name: INSULIN
DrugBank: Insulin beef (DB09456)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Insulin + rosiglitazone versus insulin monotherapy
Study: 12849762
Drug: L-dopa therapy
Normalized name: α-methyl-L-dopa
DrugBank: Methyldopa (DB00968)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: L-dopa therapy (ON condition)
Study: 12849762
Drug: No treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: No treatment (OFF condition)
Study: 29920978
Drug: Vortioxetine (5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Vortioxetine (5 to 20 mg once daily)
Study: 22324948
Drug: Chloroquine (CQ)
Normalized name: Chloroquine
DrugBank: Chloroquine (DB00608)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Chloroquine (CQ) 150 mg daily
Study: 17335316
Drug: Combination trials
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination trials (antidepressant and antipsychotic)
Study: 15064262
Drug: Dexmedetomidine 1
Normalized name: DEXMEDETOMIDINE 120MCG SUBLINGUAL FILM
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dexmedetomidine 1 micro g*kg(‐1) iv followed by 0.5 micro g*kg(‐1)*hr(‐1) infusion with morphine PCA (2 mg bolus, five minutes lockout, 2 mg*hr(‐1) infusion)
Study: 15064262
Drug: Tramadol 1.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tramadol 1.5 mg*kg(‐1) pre‐mixed with midazolam 30 micro g*kg(‐1) iv followed by tramadol PCA (20 mg bolus, five minute lockout, 20 mg*hr(‐1) infusion)
Study: 12126906
Drug: Oka/Merck varicella
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oka/Merck varicella vaccine (Group A: 50,000 PFU, Group B: 16,000 PFU)
Study: 7861197
Drug: Brodimoprim 200mg
Normalized name: brodimoprim
DrugBank: Brodimoprim (DB13795)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Brodimoprim 200mg tablet once daily for 8 to 12 days (including a loading dose of 2 tablets on the first day)
Study: 7861197
Drug: Doxycycline 100mg
Normalized name: Doxycycline
DrugBank: Doxycycline (DB00254)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Doxycycline 100mg tablet once daily for 8 to 12 days (including a loading dose of 2 tablets on the first day)
Study: 28318515
Drug: Statin administration
Approvals — FDA: no, EMA: no, PMDA: no
Description: Statin administration 24 hours or less preoperatively
Study: 28318515
Drug: Statin administration
Approvals — FDA: no, EMA: no, PMDA: no
Description: Statin administration 24 to 72 hours preoperatively
Study: 28318515
Drug: Statin administration
Approvals — FDA: no, EMA: no, PMDA: no
Description: Statin administration more than 72 hours or no dose
Study: 28318515
Drug: Statin dose
Approvals — FDA: no, EMA: no, PMDA: no
Description: Statin dose of 20 mg or less
Study: 28318515
Drug: Statin dose
Approvals — FDA: no, EMA: no, PMDA: no
Description: Statin dose of more than 20 mg
Study: 7639374
Drug: Interpleural infusion
Normalized name: Duo Fusion
DrugBank: Magnesium hydroxide (DB09104)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Interpleural infusion of 2% lidocaine
Study: 31228006
Drug: Propofol (2.0,
Approvals — FDA: no, EMA: no, PMDA: no
Description: Propofol (2.0, 1.5, and 1.2 mg/kg for young, middle, and elderly groups respectively)
Study: 31228006
Drug: Thiopental (5.0,
Approvals — FDA: no, EMA: no, PMDA: no
Description: Thiopental (5.0, 4.0, and 3.0 mg/kg for young, middle, and elderly groups respectively)
Study: 25158925
Drug: Lubiprostone (48
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lubiprostone (48 μg/day) for 4 weeks
Study: 25158925
Drug: Lubiprostone (24
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lubiprostone (24 μg twice daily) for 48 weeks
Study: 21461761
Drug: Placebo (6
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo (6 mg/kg)
Study: 2418707
Drug: 375 Units
Normalized name: CHOLECALCIFEROL 3375 UNITS/FOLIC 1MG CAP
Approvals — FDA: no, EMA: no, PMDA: no
Description: 375 Units of Heparin/kg body weight injected into the right atrium (group 1)
Study: 2418707
Drug: 375 Units
Normalized name: CHOLECALCIFEROL 3375 UNITS/FOLIC 1MG CAP
Approvals — FDA: no, EMA: no, PMDA: no
Description: 375 Units of Heparin/kg body weight injected into the ascending aorta (group 2)
Study: 29371133
Drug: Inhaled hypertonic
Approvals — FDA: no, EMA: no, PMDA: no
Description: Inhaled hypertonic saline (HS), 7% NaCl, 4 mL, single dose
Study: 27347698
Drug: Craniosacral therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Craniosacral therapy (10 sessions)
Study: 25152289
Drug: Priming dose
Normalized name: epinephrine
DrugBank: Epinephrine (DB00668)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Priming dose of rocuronium 0.06 mg/kg (Group II)
Study: 25152289
Drug: Priming dose
Normalized name: epinephrine
DrugBank: Epinephrine (DB00668)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Priming dose of rocuronium 0.075 mg/kg (Group III)
Study: 25152289
Drug: Priming dose
Normalized name: epinephrine
DrugBank: Epinephrine (DB00668)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Priming dose of rocuronium 0.1 mg/kg (Group IV)
Study: 25152289
Drug: Saline placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Saline placebo injection (Group I)
Study: 18154225
Drug: Preventive educational
Approvals — FDA: no, EMA: no, PMDA: no
Description: Preventive educational programme including topical application of 1.23% acidulated fluoride phosphate, pH 3.5, every 6 months
Study: 10361960
Drug: Moclobemide (450
Approvals — FDA: no, EMA: no, PMDA: no
Description: Moclobemide (450 mg)
Study: 7742165
Drug: Placebo administration
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo administration to healthy volunteers with behaviour pattern A (competitive and aggressive)